TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Catalyst Pharma ( (CPRX) ) just unveiled an announcement.
On August 6, 2025, Catalyst Pharmaceuticals announced that the National Comprehensive Cancer Network Clinical Practice Guidelines for Small Cell Lung Cancer now include Lambert Eaton myasthenic syndrome (LEMS), amifampridine, and tests for voltage-gated calcium channel antibodies. This update aims to improve diagnosis and treatment of LEMS in SCLC patients, potentially enhancing patient outcomes by raising clinical awareness and promoting comprehensive neurological evaluations.
The most recent analyst rating on (CPRX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Catalyst Pharma stock, see the CPRX Stock Forecast page.
Spark’s Take on CPRX Stock
According to Spark, TipRanks’ AI Analyst, CPRX is a Outperform.
Catalyst Pharma’s strong financial performance and positive earnings call are the most significant factors driving the stock’s score. While technical indicators suggest caution, the company’s strategic initiatives and valuation support a favorable outlook.
To see Spark’s full report on CPRX stock, click here.
More about Catalyst Pharma
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients with rare and difficult-to-treat diseases. Headquartered in Coral Gables, Florida, Catalyst prioritizes patient care and accessibility through a comprehensive suite of support services. The company has been recognized as one of America’s Most Successful Mid-Cap Companies and one of North America’s Fastest-Growing Companies.
Average Trading Volume: 1,286,697
Technical Sentiment Signal: Buy
Current Market Cap: $2.71B
Find detailed analytics on CPRX stock on TipRanks’ Stock Analysis page.